Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 2/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | POLA1 | P09884 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.34 |
| ▸ | PPARG | P37231 | 6/20 | 0.34 |
| ▸ | PPARD | Q03181 | 6/20 | 0.34 |
| ▸ | PPARA | Q07869 | 6/20 | 0.34 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.34 |
| ▸ | TLR2 | O60603 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | FABP4 | P15090 | 2/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL554182 | 0.94 | AKR1B1 (0.43) | APEX1CES1CES2TSHRPOLB | |
| SCHEMBL555676 | 0.88 | TSHR (0.40) | CES1CES2TSHRKDM4EPOLB | |
| SCHEMBL7772114 | 0.85 | CES1 (0.38) | APEX1CES1CES2TSHRPOLB | |
| SCHEMBL9327902 | 0.85 | CES1 (0.38) | APEX1CES1CES2TSHRPOLB | |
| SCHEMBL1581723 | 0.85 | CES1 (0.38) | APEX1CES1CES2TSHRALDH1A1 | |
| SCHEMBL3977487 | 0.85 | CES1 (0.38) | APEX1CES1CES2TSHRALDH1A1 | |
| SCHEMBL4795564 | 0.83 | FAAH (0.44) | APEX1CES1CES2TSHRALDH1A1 | |
| SCHEMBL9068911 | 0.82 | CES1 (0.42) | APEX1CES1CES2TSHRPOLB | |
| SCHEMBL1034581 | 0.82 | CES1 (0.42) | APEX1CES1CES2TSHRPOLB | |
| SCHEMBL4466781 | 0.81 | HCAR2 (0.49) | CES1CES2TSHRALDH1A1HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220105064-A1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER | BIOGEN SWISS MFG GMBH (CH) | 2022-04-07 | — | — | US | claimed |
| US-20220079884-A1 | PHARMACEUTICAL FORMULATION COMPRISING ONE OR MORE FUMARIC ACID ESTERS IN AN EROSION MATRIX | BIOGEN SWISS MFG GMBH (CH) | 2022-03-17 | — | — | US | claimed |
| US-11229619-B2 | Controlled release pharmaceutical compositions comprising a fumaric acid ester | BIOGEN SWISS MANUFACTURING GMBH (CH) | 2022-01-25 | — | — | US | claimed |
| US-20180221284-A1 | PHARMACEUTICAL FORMULATION COMPRISING ONE OR MORE FUMARIC ACID ESTERS IN AN EROSION MATRIX | BIOGEN SWISS MANUFACTURING GMBH (CH) | 2018-08-09 | — | — | US | claimed |
| US-20150272894-A1 | PHARMACEUTICAL FORMULATION COMPRISING ONE OR MORE FUMARIC ACID ESTERS IN AN EROSION MATRIX | BIOGEN SWISS MANUFACTURING GMBH (CH) | 2015-10-01 | — | — | US | claimed |
| US-20130259906-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ONE OR MORE FUMARIC ACID ESTERS | FORWARD PHARMA A/S (DK) | 2013-10-03 | — | — | US | claimed |
| US-20120034303-A1 | PHARMACEUTICAL FORMULATION COMPRISING ONE OR MORE FUMARIC ACID ESTERS IN AN EROSION MATRIX | FORWARD PHARMA A/S (DK) | 2012-02-09 | — | — | US | claimed |
| US-20120034274-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ONE OR MORE FUMARIC ACID ESTERS | FORWARD PHARMA A/S (DK) | 2012-02-09 | — | — | US | claimed |
| EP-2379063-A1 | PHARMACEUTICAL FORMULATION COMPRISING ONE OR MORE FUMARIC ACID ESTERS IN AN EROSION MATRIX | Forward Pharma A/S (DK) | 2011-10-26 | — | — | EP | claimed |
| EP-2379062-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ONE OR MORE FUMARIC ACID ESTERS | Forward Pharma A/S (DK) | 2011-10-26 | — | — | EP | claimed |
| WO-2010079222-A1 | PHARMACEUTICAL FORMULATION COMPRISING ONE OR MORE FUMARIC ACID ESTERS IN AN EROSION MATRIX | FORWARD PHARMA A/S (DK) | 2010-07-15 | — | — | WO | claimed |
| WO-2010079221-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ONE OR MORE FUMARIC ACID ESTERS | FORWARD PHARMA A/S (DK) | 2010-07-15 | — | — | WO | claimed |
| US-20240240229-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2024-07-18 | — | — | US | disclosed |
| US-20220105064-A1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER | BIOGEN SWISS MFG GMBH (CH) | 2022-04-07 | — | — | US | disclosed |
| US-20220079884-A1 | PHARMACEUTICAL FORMULATION COMPRISING ONE OR MORE FUMARIC ACID ESTERS IN AN EROSION MATRIX | BIOGEN SWISS MFG GMBH (CH) | 2022-03-17 | — | — | US | disclosed |
| US-11229619-B2 | Controlled release pharmaceutical compositions comprising a fumaric acid ester | BIOGEN SWISS MANUFACTURING GMBH (CH) | 2022-01-25 | — | — | US | disclosed |
| WO-2007006307-A2 | NOVEL SALTS OF FUMARIC ACID MONOALKYLESTERS AND THEIR PHARMACEUTICAL USE | ADITECH PHARMA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007006308-A1 | NOVEL GLUCOPYRANOSE ESTERS AND GLUCOFURANOSE ESTERS OF ALKYL- FU MARATES AND THEIR PHARMACEUTICAL USE | ADITECH PHARMA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006050730-A1 | NOVEL SALTS OF FUMARIC ACID MONOALKYLESTERS AND THEIR PHARMACEUTICAL USE | ADITECH PHARMA AB (SE) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006037342-A2 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER | ADITECH PHARMA AB (SE) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240240229-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | GSTM1, GSTM2, GSTA1 | APEX1 623/4885CES1 293/4885CES2 2039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.